A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study (Q46141389)
Jump to navigation
Jump to search
scientific article published in June 1995
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study |
scientific article published in June 1995 |
Statements
1 reference
A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study (English)
1 reference
Blazar BR
1 reference
Bauer M
1 reference
Reaman GH
1 reference
Hank JA
1 reference
Cairo MS
1 reference
Anderson P
1 reference
Frierdich S
1 reference
Sondel PM
1 reference
1 June 1995
1 reference
1 reference
75
1 reference
12
1 reference
2959-2965
1 reference